• Investors may be wondering if Capricor Therapeutics at around US$33.94 is still offering value after a strong run, or if most of the opportunity is already reflected in the price.
• The stock has returned 1.1% over the last week, 6.2% over the past month and 19.9% year to date, with a very large 1 year return of 386.9% and around 7x over 3 years. This naturally raises questions about the current balance of risk and reward.
• Recent coverage has focused on Capricor Therapeutics because of its sharp multi year share price performance and ongoing interest in its sector, which keeps investor attention on whether the current price aligns with fundamentals. This background makes it useful to step back and look at what different valuation tools are indicating about the stock today.
• Simply Wall St currently gives Capricor Therapeutics a valuation score of 3/6, and the next sections will walk through the standard valuation approaches investors often use. The article will finish with a broader way of thinking about what that score may mean for individual investors.

Approach 1: Capricor Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting its future cash flows and then discounting those back to a present value.

For Capricor Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The company currently reports last twelve month free cash flow of $81.54 million in outflows. Analysts provide specific free cash flow estimates out to 2030, including $104 million in 2026 and $413.5 million in 2030. Beyond those analyst inputs, Simply Wall St extrapolates further annual projections through to 2035 using its own growth assumptions.

After discounting these projected cash flows, the model arrives at an estimated intrinsic value of about $313.25 per share. Compared with the recent share price of around $33.94, this implies an intrinsic discount of 89.2%, which points to the stock trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Capricor Therapeutics is undervalued by 89.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Capricor Therapeutics Price vs Book

For companies where book value is a meaningful anchor, the price to book, or P/B, ratio is a useful way to think about what you are paying relative to the net assets on the balance sheet. It is especially common in sectors where earnings can be volatile or not yet firmly established.

In general, higher growth expectations and lower perceived risk can justify a higher “normal” or “fair” P/B multiple, while slower growth or higher risk tend to support a lower multiple. With Capricor Therapeutics, the current P/B ratio is about 6.42x, compared with an average of 2.39x for the Biotechs industry and about 6.31x for its peers.

Simply Wall St also calculates a proprietary “Fair Ratio,” which is the P/B multiple that might be expected given factors such as earnings growth, profit margins, size, risk profile and the characteristics of the Biotechs industry. This Fair Ratio can be more tailored than a simple comparison with peers or the broad industry because it pulls these influences together into a single reference point. In this case, the Fair Ratio is not available, so it is not possible to use this framework to judge whether the current 6.42x P/B suggests the stock is overvalued, undervalued or roughly in line with its fundamentals.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Capricor Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the story you believe about Capricor Therapeutics, such as whether future earnings are closer to the bullish US$291.5 million case with a Fair Value of US$63.00 or the cautious US$11.1 million case with a Fair Value of US$12.00. Narratives then link that story to a full forecast of revenue, margins and P/E, and compare your Fair Value with the current price on Simply Wall St's Community page. Narratives are easy to set up, update automatically when fresh news or earnings arrive, and help you decide whether the stock looks expensive or cheap against the story you find most reasonable.

Do you think there's more to the story for Capricor Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.